Herpes simplex virus - Revision history

Aidan at 18:18, 14 January 2026

2026-01-14T18:18:16Z

← Older revision		Revision as of 18:18, 14 January 2026
Line 7:		Line 7:
	===Microbiology===		===Microbiology===

	*Enveloped, [[Baltimore classification::dsDNA\|double-stranded DNA virus]]		*Enveloped, [[Baltimore classification::dsDNA virus\|double-stranded DNA virus]]
	*HSV-1 and HSV-2 are morphologically and genetically distinct viruses		*HSV-1 and HSV-2 are morphologically and genetically distinct viruses
	*Can be infected with both		*Can be infected with both

2026-01-14T18:17:59Z

← Older revision		Revision as of 18:17, 14 January 2026
Line 1:		Line 1:
		⚫	==Background==
⚫	*Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Herpesviridae]] family

		⚫	*Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Herpesviridae]] family and share about 70% of genetic material
	*Cause typical painful vesicular lesions on labia or external genitals		*Cause typical painful vesicular lesions on labia or external genitals
	*Occasionally cause a viral encephalitis		*Occasionally cause a viral encephalitis

⚫	==Background==

	===Microbiology===		===Microbiology===

	*Enveloped, double-stranded DNA virus		*Enveloped, [[Baltimore classification::dsDNA\|double-stranded DNA virus]]
	*HSV-1 and HSV-2 are morphologically and genetically distinct viruses		*HSV-1 and HSV-2 are morphologically and genetically distinct viruses
	*Can be infected with both		*Can be infected with both
Line 13:		Line 13:
	===Mechanisms of Resistance===		===Mechanisms of Resistance===

	*'''Resistance''' to acyclovir is usually conferred by a deficiency in thymidine kinase (which phosphorylates acyclovir)		*'''Resistance''' to [[acyclovir]] is usually conferred by a deficiency in thymidine kinase (which phosphorylates acyclovir)
	**Will also be resistant to valacyclovir and famciclovir		**Will also be resistant to [[valacyclovir]] and [[famciclovir]]

	===Epidemiology===		===Epidemiology===

2025-06-13T17:11:03Z

← Older revision		Revision as of 17:11, 13 June 2025
Line 227:		Line 227:

	*[[Is treated by::Acyclovir]] 10 mg/kg IV q8h for 21 days		*[[Is treated by::Acyclovir]] 10 mg/kg IV q8h for 21 days
	*Duration 21 days for encephalitis or ~~7 to~~ 10 days for meningitis		*Duration 21 days for encephalitis or 10 days for meningitis (can transition to oral [[valacyclovir]] 1 g q8h to facilitate discharge)
	*In neonates, this is followed by oral suppressive therapy		*In neonates, this is followed by oral suppressive therapy

2025-05-01T14:11:17Z

Management

← Older revision		Revision as of 14:11, 1 May 2025
Line 200:		Line 200:
	*HIV patients		*HIV patients
	**Recurrence		**Recurrence
	***[[Is treated by::~~acyclovir~~]] 400 mg po tid, [[Is treated by::valacyclovir]] 1 g po bid, [[Is treated by::famciclovir]] 500 mg po tid		***[[Is treated by::Acyclovir]] 400 mg po tid, [[Is treated by::valacyclovir]] 1 g po bid, [[Is treated by::famciclovir]] 500 mg po tid
	***Duration 5 to 10 days		***Duration 5 to 10 days
	**Suppressive therapy		**Suppressive therapy
	**[[Is treated by::Acyclovir]] 400 to 800 mg po bid to tid, [[Is treated by::famciclovir]] 500 mg po bid, or [[Is treated by::valacyclovir]] 500 mg po bid		***[[Is treated by::Acyclovir]] 400 to 800 mg po bid to tid, [[Is treated by::famciclovir]] 500 mg po bid, or [[Is treated by::valacyclovir]] 500 mg po bid
	*Severe infections, including CNS or ocular involvement, or disseminated disease		*Severe infections, including CNS or ocular involvement, or disseminated disease
	**[[Is treated by::Acyclovir]] 5 to 10 mg/kg IV q8h for 5 to 7 days and until clinical resolution		**[[Is treated by::Acyclovir]] 5 to 10 mg/kg IV q8h for 5 to 7 days and until clinical resolution

2023-05-02T16:29:24Z

Genital and Rectal Herpes

← Older revision		Revision as of 16:29, 2 May 2023
Line 200:		Line 200:
	*HIV patients		*HIV patients
	**Recurrence		**Recurrence
	***[[Is treated by::acyclovir~~\|Is treated by::Acyclovir~~]] 400 mg po tid, [[Is treated by::valacyclovir]] 1 g po bid, [[Is treated by::famciclovir]] 500 mg po tid		***[[Is treated by::acyclovir]] 400 mg po tid, [[Is treated by::valacyclovir]] 1 g po bid, [[Is treated by::famciclovir]] 500 mg po tid
	***Duration 5 to 10 days		***Duration 5 to 10 days
	**Suppressive therapy		**Suppressive therapy

2022-03-12T21:37:06Z

Visceral and Pulmonary Herpes

← Older revision		Revision as of 21:37, 12 March 2022
Line 140:		Line 140:
	*'''Esophagitis''' is more common in patients with advanced HIV		*'''Esophagitis''' is more common in patients with advanced HIV
	**Symptoms include odynophagia, dysphagia, chest pain, and weight loss		**Symptoms include odynophagia, dysphagia, chest pain, and weight loss
	*'''Pneumonitis''' may occur in patients with ~~immunodupression~~		*'''Pneumonitis''' may occur in patients with immunosuppression
	**Focal necrotizing pneumonitis or bilateral interstitial pneumonitis, depending on pattern of spread		**Focal necrotizing pneumonitis or bilateral interstitial pneumonitis, depending on pattern of spread
	**80% mortality		**80% mortality

2020-12-03T16:15:31Z

Management

2020-09-18T17:39:48Z

Text replacement - "[[Human herpesvirus" to "[[Herpesviridae"

← Older revision		Revision as of 17:39, 18 September 2020
Line 1:		Line 1:
	*Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[~~Human herpesvirus~~]] family		*Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Herpesviridae]] family
	*Cause typical painful vesicular lesions on labia or external genitals		*Cause typical painful vesicular lesions on labia or external genitals
	*Occasionally cause a viral encephalitis		*Occasionally cause a viral encephalitis

2020-09-13T22:03:30Z

2020-08-05T14:08:25Z

Primary infection

← Older revision		Revision as of 14:08, 5 August 2020
Line 35:		Line 35:

	=== Primary infection ===		=== Primary infection ===
	* Incubation period usually within 5 days for primary infection		* Incubation period usually [[Usual incubation period::within 5 days]] for primary infection
	* Mucocutaneous lesiosn may become secondarily infected		* Mucocutaneous lesiosn may become secondarily infected